Toll Free: 1-888-928-9744

Osteoarthritis - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 308 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Osteoarthritis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Osteoarthritis - Pipeline Review, H1 2016', provides an overview of the Osteoarthritis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
- The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
- The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Osteoarthritis Overview 12 Therapeutics Development 13 Pipeline Products for Osteoarthritis - Overview 13 Pipeline Products for Osteoarthritis - Comparative Analysis 14 Osteoarthritis - Therapeutics under Development by Companies 15 Osteoarthritis - Therapeutics under Investigation by Universities/Institutes 21 Osteoarthritis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Osteoarthritis - Products under Development by Companies 25 Osteoarthritis - Products under Investigation by Universities/Institutes 32 Osteoarthritis - Companies Involved in Therapeutics Development 33 A. Menarini Industrie Farmaceutiche Riunite Srl 33 AbbVie Inc. 34 Abiogen Pharma S.p.A. 35 Ablynx NV 36 Achelios Therapeutics, Inc. 37 Addex Therapeutics Ltd 38 Akari Therapeutics, Plc 39 Amura Holdings Limited 40 Arcarios BV 41 Asahi Kasei Pharma Corp. 42 Asklepios BioPharmaceutical, Inc. 43 Astellas Pharma Inc. 44 Asterias Biotherapeutics, Inc. 45 Axsome Therapeutics, Inc. 46 Biopharm GmbH 47 Can-Fite BioPharma Ltd. 48 Cara Therapeutics, Inc. 49 Cardax Pharmaceuticals, Inc. 50 Cellceutix Corporation 51 Cellular Biomedicine Group, Inc. 52 Chong Kun Dang Pharmaceutical Corp. 53 Dong-A ST Co., Ltd. 54 Eli Lilly and Company 55 Evgen Pharma PLC 56 Galapagos NV 57 Genequine Biotherapeutics GmbH 58 GlaxoSmithKline Plc 59 IntelliCell BioSciences Inc. 60 Jeil Pharmaceutical Co., Ltd. 61 Jenrin Discovery, Inc. 62 K-Stemcell Co., Ltd. 63 Levolta Pharmaceuticals, Inc. 64 Medivir AB 65 Merck KGaA 66 Mesoblast Limited 67 Mor Research Application Ltd 68 NicOx S.A. 69 Nordic Bioscience A/S 70 Novartis AG 71 Ocata Therapeutics, Inc. 72 Omeros Corporation 73 Ono Pharmaceutical Co., Ltd. 74 OrthoCyte Corporation 75 Osteologix Holdings Plc 76 Pfizer Inc. 77 Pharmalink AB 78 PLx Pharma Inc. 79 ProteoThera, Inc. 80 Regeneus Ltd 81 ReqMed Company, Ltd. 82 Sanofi 83 Seikagaku Corporation 84 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 85 STELIS Biopharma Pvt. Ltd. 86 Stempeutics Research Private Limited 87 Symic Biomedical, Inc. 88 Takeda Pharmaceutical Company Limited 89 TissueGene, Inc. 90 Upsher-Smith Laboratories, Inc. 91 Yooyoung Pharmaceutical Co., Ltd. 92 Yuhan Corporation 93 Yungjin Pharm. Co., Ltd. 94 Zimmer Biomet Holdings, Inc. 95 Zynerba Pharmaceuticals, Inc. 96 Osteoarthritis - Therapeutics Assessment 97 Assessment by Monotherapy Products 97 Assessment by Combination Products 98 Assessment by Target 99 ssessment by Mechanism of Action 103 Assessment by Route of Administration 106 Assessment by Molecule Type 108 Drug Profiles 110 (apocynin + paeonol) - Drug Profile 110 (clodronate disodium + hyaluronic acid) - Drug Profile 111 ABT-981 - Drug Profile 112 AlloJoin - Drug Profile 113 AM-3701 - Drug Profile 114 AM-3876 - Drug Profile 115 Anatabine - Drug Profile 116 Antibody for Osteoarthritis - Drug Profile 118 Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 119 ARC-118 - Drug Profile 120 AS-001 - Drug Profile 121 ASP-7962 - Drug Profile 122 BNP-OA - Drug Profile 123 BRM-421 - Drug Profile 124 CDX-085 - Drug Profile 125 celecoxib - Drug Profile 127 CHND-1 - Drug Profile 128 CKD-941 - Drug Profile 130 clodronate disodium - Drug Profile 131 CR-8357 - Drug Profile 132 CR-845 - Drug Profile 133 CRB-0017 - Drug Profile 136 CS-30MS02 - Drug Profile 137 DA-5202 - Drug Profile 138 DIS-BIO-EPS - Drug Profile 139 DNX-314 - Drug Profile 140 Drug for Bone Diseases and Osteoarthritis - Drug Profile 141 Drug for Osteoarthritis - Drug Profile 142 Drugs to Inhibit Renin Angiotensin for Osteoarthritis - Drug Profile 143 Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 144 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 145 duloxetine hydrochloride DR - Drug Profile 146 fasitibant chloride - Drug Profile 148 GLPG-1972 - Drug Profile 149 GQ-203 - Drug Profile 150 GQ-303 - Drug Profile 151 GSK-2394002 - Drug Profile 152 GZ-389988 - Drug Profile 153 JD-4000 Series - Drug Profile 154 Kartogenin - Drug Profile 155 KBP-056 - Drug Profile 156 ketoprofen - Drug Profile 157 KM-278 - Drug Profile 159 LEVI-04 - Drug Profile 160 LH-023 - Drug Profile 161 LNA-043 - Drug Profile 162 MIV-711 - Drug Profile 163 Monoclonal Antibodies for Inflammation and Osteoarthritis - Drug Profile 164 Monoclonal Antibody for Osteoarthritis - Drug Profile 166 MOR-106 - Drug Profile 167 MSBCAR-001 - Drug Profile 168 naproxcinod - Drug Profile 169 NBS-101 - Drug Profile 171 NStride APS - Drug Profile 172 OAX-1 - Drug Profile 173 ONO-4474 - Drug Profile 174 OTXCP-03 - Drug Profile 175 OTXCP-07 - Drug Profile 176 pentosan polysulfate sodium - Drug Profile 177 Peptide for Osteoarthritis - Drug Profile 179 piclidenoson - Drug Profile 180 PL-1100 - Drug Profile 182 PRO-1 - Drug Profile 183 Progenza - Drug Profile 185 Protein for Osteoarthritis - Drug Profile 186 Protein for Osteoarthritis and Asthma - Drug Profile 187 Protein for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 188 Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome - Drug Profile 189 PRX-167700 - Drug Profile 191 Recombinant Peptides for Osteoarthritis - Drug Profile 192 Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 193 Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 194 Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile 195 ReJoin - Drug Profile 196 Salmon Calcitonin - Drug Profile 197 SAR-396049 - Drug Profile 199 SB-061 - Drug Profile 200 SBL-005 - Drug Profile 201 SI-613 - Drug Profile 202 SM-04690 - Drug Profile 203 Small Molecule for Degenerative Arthritis - Drug Profile 204 Small Molecule for Osteoarthritis - Drug Profile 205 Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 206 Small Molecule to Inhibit MMP13 for Osteoarthritis - Drug Profile 207 Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 208 Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 209 Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 210 Small Molecules for Osteoarthritis - Drug Profile 211 Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 212 Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 213 Small Molecules to Inhibit Complement System Protein for Osteoarthritis - Drug Profile 214 Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile 215 Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 216 sprifermin - Drug Profile 217 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 219 Stem Cell therapy for CNS, CVS, Dermatological, Immnuological and Metabolic Disorders - Drug Profile 220 Stem Cell Therapy for Degenerative Arthritis - Drug Profile 221 Stem Cell Therapy for Knee Osteoarthritis - Drug Profile 222 Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile 223 Stem Cell Therapy for Osteoarthritis - Drug Profile 225 Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases - Drug Profile 226 Stempeucel - Drug Profile 228 Stromal Cell Therapy for Arthritis - Drug Profile 231 Sulforadex - Drug Profile 232 tonogenchoncel-L - Drug Profile 234 TPX-100 - Drug Profile 236 TRBN-0224 - Drug Profile 237 UGP-302 - Drug Profile 238 VOLT-01 - Drug Profile 240 X-0002 - Drug Profile 241 XT-101 - Drug Profile 243 XT-150 - Drug Profile 244 YH-14619 - Drug Profile 245 YRA-1909 - Drug Profile 246 YY-1201 - Drug Profile 247 zoledronic acid - Drug Profile 248 ZYN-002 - Drug Profile 250 Osteoarthritis - Recent Pipeline Updates 251 Osteoarthritis - Dormant Projects 281 Osteoarthritis - Discontinued Products 290 Osteoarthritis - Product Development Milestones 292 Featured News & Press Releases 292 Appendix 299 Methodology 299 Coverage 299 Secondary Research 299 Primary Research 299 Expert Panel Validation 299 Contact Us 299 Disclaimer 300
List of Tables
Number of Products under Development for Osteoarthritis, H1 2016 21 Number of Products under Development for Osteoarthritis - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Development by Companies, H1 2016 (Contd..1) 24 Number of Products under Development by Companies, H1 2016 (Contd..2) 25 Number of Products under Development by Companies, H1 2016 (Contd..3) 26 Number of Products under Development by Companies, H1 2016 (Contd..4) 27 Number of Products under Development by Companies, H1 2016 (Contd..5) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Development, H1 2016 32 Products under Development by Companies, H1 2016 33 Products under Development by Companies, H1 2016 (Contd..1) 34 Products under Development by Companies, H1 2016 (Contd..2) 35 Products under Development by Companies, H1 2016 (Contd..3) 36 Products under Development by Companies, H1 2016 (Contd..4) 37 Products under Development by Companies, H1 2016 (Contd..5) 38 Products under Development by Companies, H1 2016 (Contd..6) 39 Products under Investigation by Universities/Institutes, H1 2016 40 Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 41 Osteoarthritis - Pipeline by AbbVie Inc., H1 2016 42 Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H1 2016 43 Osteoarthritis - Pipeline by Ablynx NV, H1 2016 44 Osteoarthritis - Pipeline by Achelios Therapeutics, Inc., H1 2016 45 Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2016 46 Osteoarthritis - Pipeline by Akari Therapeutics, Plc, H1 2016 47 Osteoarthritis - Pipeline by Amura Holdings Limited, H1 2016 48 Osteoarthritis - Pipeline by Arcarios BV, H1 2016 49 Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp., H1 2016 50 Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016 51 Osteoarthritis - Pipeline by Astellas Pharma Inc., H1 2016 52 Osteoarthritis - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 53 Osteoarthritis - Pipeline by Axsome Therapeutics, Inc., H1 2016 54 Osteoarthritis - Pipeline by Biopharm GmbH, H1 2016 55 Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H1 2016 56 Osteoarthritis - Pipeline by Cara Therapeutics, Inc., H1 2016 57 Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 58 Osteoarthritis - Pipeline by Cellceutix Corporation, H1 2016 59 Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 60 Osteoarthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 61 Osteoarthritis - Pipeline by Dong-A ST Co., Ltd., H1 2016 62 Osteoarthritis - Pipeline by Eli Lilly and Company, H1 2016 63 Osteoarthritis - Pipeline by Evgen Pharma PLC, H1 2016 64 Osteoarthritis - Pipeline by Galapagos NV, H1 2016 65 Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2016 66 Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2016 67 Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H1 2016 68 Osteoarthritis - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 69 Osteoarthritis - Pipeline by Jenrin Discovery, Inc., H1 2016 70 Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H1 2016 71 Osteoarthritis - Pipeline by Levolta Pharmaceuticals, Inc., H1 2016 72 Osteoarthritis - Pipeline by Medivir AB, H1 2016 73 Osteoarthritis - Pipeline by Merck KGaA, H1 2016 74 Osteoarthritis - Pipeline by Mesoblast Limited, H1 2016 75 Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2016 76 Osteoarthritis - Pipeline by NicOx S.A., H1 2016 77 Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2016 78 Osteoarthritis - Pipeline by Novartis AG, H1 2016 79 Osteoarthritis - Pipeline by Ocata Therapeutics, Inc., H1 2016 80 Osteoarthritis - Pipeline by Omeros Corporation, H1 2016 81 Osteoarthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 82 Osteoarthritis - Pipeline by OrthoCyte Corporation, H1 2016 83 Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2016 84 Osteoarthritis - Pipeline by Pfizer Inc., H1 2016 85 Osteoarthritis - Pipeline by Pharmalink AB, H1 2016 86 Osteoarthritis - Pipeline by PLx Pharma Inc., H1 2016 87 Osteoarthritis - Pipeline by ProteoThera, Inc., H1 2016 88 Osteoarthritis - Pipeline by Regeneus Ltd, H1 2016 89 Osteoarthritis - Pipeline by ReqMed Company, Ltd., H1 2016 90 Osteoarthritis - Pipeline by Sanofi, H1 2016 91 Osteoarthritis - Pipeline by Seikagaku Corporation, H1 2016 92 Osteoarthritis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 93 Osteoarthritis - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016 94 Osteoarthritis - Pipeline by Stempeutics Research Private Limited, H1 2016 95 Osteoarthritis - Pipeline by Symic Biomedical, Inc., H1 2016 96 Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 97 Osteoarthritis - Pipeline by TissueGene, Inc., H1 2016 98 Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 99 Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 100 Osteoarthritis - Pipeline by Yuhan Corporation, H1 2016 101 Osteoarthritis - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 102 Osteoarthritis - Pipeline by Zimmer Biomet Holdings, Inc., H1 2016 103 Osteoarthritis - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 104 Assessment by Monotherapy Products, H1 2016 105 Assessment by Combination Products, H1 2016 106 Number of Products by Stage and Target, H1 2016 108 Number of Products by Stage and Mechanism of Action, H1 2016 112 Number of Products by Stage and Route of Administration, H1 2016 115 Number of Products by Stage and Molecule Type, H1 2016 117 Osteoarthritis Therapeutics - Recent Pipeline Updates, H1 2016 259 Osteoarthritis - Dormant Projects, H1 2016 289 Osteoarthritis - Dormant Projects (Contd..1), H1 2016 290 Osteoarthritis - Dormant Projects (Contd..2), H1 2016 291 Osteoarthritis - Dormant Projects (Contd..3), H1 2016 292 Osteoarthritis - Dormant Projects (Contd..4), H1 2016 293 Osteoarthritis - Dormant Projects (Contd..5), H1 2016 294 Osteoarthritis - Dormant Projects (Contd..6), H1 2016 295 Osteoarthritis - Dormant Projects (Contd..7), H1 2016 296 Osteoarthritis - Dormant Projects (Contd..8), H1 2016 297 Osteoarthritis - Discontinued Products, H1 2016 298 Osteoarthritis - Discontinued Products (Contd..1), H1 2016 299


List of Figures
Number of Products under Development for Osteoarthritis, H1 2016 21 Number of Products under Development for Osteoarthritis - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Products, H1 2016 32 Assessment by Monotherapy Products, H1 2016 105 Assessment by Combination Products, H1 2016 106 Number of Products by Top 10 Targets, H1 2016 107 Number of Products by Stage and Top 10 Targets, H1 2016 107 Number of Products by Top 10 Mechanism of Actions, H1 2016 111 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 111 Number of Products by Top 10 Routes of Administration, H1 2016 114 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 114 Number of Products by Top 10 Molecule Types, H1 2016 116 Number of Products by Stage and Top 10 Molecule Types, H1 2016 116

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify